Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,054

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy

Open access
Bartalena, L, Kahaly, G J, Baldeschi, L, Dayan, C M, Eckstein, A, Marcocci, C, Marinò, M, Vaidya, B, Wiersinga, W M, _, _, _, _, Ayvaz, Goksun, Konuk, Onur, Ciric, Jasmina, Beleslin, Bijliana, Boschi, Antonella, Cristina Burlacu, Maria, Morris, Dan, Le Moli, Rosario, Marino, Antonio, McKee, Justin, Zammit, Nicola, Führer, Dagmar, Pereni, Ioana, Schittkowski, Michael, Raddatz, Dirk, Lee, Vickie, Meeran, Karim, Abeillon, Juliette, Soui Thcong, Thia, Ponto, Katharina, Muller, Ilaria, Currò, Nicola, Hintschich, Christoph, Gärtner, Roland, Pearce, Simon, Clarke, Lucy, Brix, Thomas, Bechtold, Dorte, Rudovfsky, Gottfried, Fichter, Nicole, Du Pasquier, Laurence, Meney, Julia, Menconi, Francesca, Lanzolla, Giulia, Sundar, Gangadhara, Peiling Yung, Samantha, Boboridis, Kostas, Anagnostis, Panagiotis, Pérez Lopez, Marta, Javier Sanchez, Carlos, Laura Tanda, Maria, Donati, Simone, Papp, Andrea, Li, Shuren, Jablonska, Anna, Miskiewicz, Piotr, Juri Mandic, Jelena, Baretic, Maja·2021·European Journal of Endocrinology

Abstract

Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease (GD). Choice of treatment should be based on the assessment of clinical activity and severity of GO. Early referral to specialized centers is fundamental for most patients with GO. Risk factors include smoking, thyroid dysfunction, high serum level of thyrotropin receptor antibodies, radioactive iodine (RAI) treatment, and hypercholesterolemia. In mild and active GO, control of risk factors, local treatments, and selenium (selenium-deficient areas) are usually sufficient; if RAI treatment is selected to manage GD, low-dose oral prednisone prophylaxis is needed, especially if risk factors coexist. For both active moderate-to-severe and sight-threatening GO, antithyroid drugs are preferred when managing Graves’ hyperthyroidism. In moderate-to-severe and active GO i.v. glucocorticoids are more effective and better tolerated than oral glucocorticoids. Based on current evidence and efficacy/safety profile, costs and reimbursement, drug availability, long-term effectiveness, and patient choice after extensive counseling, a combination of i.v. methylprednisolone and mycophenolate sodium is recommended as first-line treatment. A cumulative dose of 4.5 g of i.v. methylprednisolone in 12 weekly infusions is the optimal regimen. Alternatively, higher cumulative doses not exceeding 8 g can be used as monotherapy in most severe cases and constant/inconstant diplopia. Second-line treatments for moderate-to-severe and active GO include (a) the second course of i.v. methylprednisolone (7.5 g) subsequent to careful ophthalmic and biochemical evaluation, (b) oral prednisone/prednisolone combined with either cyclosporine or azathioprine; (c) orbital radiotherapy combined with oral or i.v. glucocorticoids, (d) teprotumumab; (e) rituximab and (f) tocilizumab. Sight-threatening GO is treated with several high single doses of i.v. methylprednisolone per week and, if unresponsive, with urgent orbital decompression. Rehabilitative surgery (orbital decompression, squint, and eyelid surgery) is indicated for inactive residual GO manifestations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-21-0479

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 1,054

Metadata

Authors
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., _, _., Ayvaz, G., Konuk, O., Ciric, J., Beleslin, B., Boschi, A., Cristina Burlacu, M., Morris, D., Le Moli, R., Marino, A., McKee, J., Zammit, N., Führer, D., Pereni, I., Schittkowski, M., Raddatz, D., Lee, V., Meeran, K., Abeillon, J., Soui Thcong, T., Ponto, K., Muller, I., Currò, N., Hintschich, C., Gärtner, R., Pearce, S., Clarke, L., Brix, T., Bechtold, D., Rudovfsky, G., Fichter, N., Du Pasquier, L., Meney, J., Menconi, F., Lanzolla, G., Sundar, G., Peiling Yung, S., Boboridis, K., Anagnostis, P., Pérez Lopez, M., Javier Sanchez, C., Laura Tanda, M., Donati, S., Papp, A., Li, S., Jablonska, A., Miskiewicz, P., Juri Mandic, J., & Baretic, M.
Venue
European Journal of Endocrinology
Published
2021-10-01
Volume
185
Issue
4
Pages
G43-G67
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W3186410608
Cited by
1,054
References
8
FWCI
80.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. https://app.cochat.ai/papers/10.1530/eje-21-0479
The paper
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., _, _., Ayvaz, G., Konuk, O., Ciric, J., Beleslin, B., Boschi, A., Cristina Burlacu, M., Morris, D., Le Moli, R., . . . Baretic, M. (2021). The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. European Journal of Endocrinology. https://doi.org/10.1530/eje-21-0479

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.